We report a case of a vertically infected woman treated with darunavir/ritonavir plus a standard backbone before pregnancy. The analysis of darunavir/ritonavir concentrations in peripheral maternal plasma throughout pregnancy, as well as in umbilical cord blood at delivery, showed low levels of darunavir in the mother and limited transfer across the placenta.
Di GiambenedettoS., De LucaA., VillaniP.Atazanavir and lopinavir with ritonavir alone or in combination: analysis of pharmacokinetic interaction and predictors of drug exposure.HIV Med2008; 9: 239–245.
3.
FabbianiS., Di GiambenedettoS., RagazzoniE.Pharmacokinetic variability of darunavir and raltegravir in routine clinical practice.10th International Workshop on Clinical Pharmacology of HIV Therapy. 15–17 April 2009, Amsterdam, the Netherlands. Poster 11.
4.
British HIV Association and Children's HIV Association guidelines for the management of HIV infection in pregnant women 2008. (Accessed 20 August 2009.) Available from http://www.bhiva.org.
5.
SekarV.J., LefebvreE., De PaepeE.Pharmacokinetic interaction between darunavir boosted with ritonavir and omeprazole or ranitidine in human immunodeficiency virus-negative healthy volunteers.Antimicrob Agents Chemother2007; 51: 958–961.
6.
BoffitoM., WinstonA., JacksonA.Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance.AIDS2007; 21: 1449–1455.
7.
SekarV., de MeyerS., VangeneugdenT.Absence of TMC114 exposure-efficacy and exposure-safety relationships in POWER 3.16th International Conference on AIDS. 13–18 August 2006, Toronto, ON, Canada. Abstract TuPe0078.
8.
AndersonG.D.Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach.Clin Pharmacokinet2005; 44: 989–1008.
9.
KrauerB., KrauerF., HyttenF.E.Drug disposition and pharmacokinetics in the maternal-placental-fetal unit.Pharmacol Ther1980; 10: 301–328.
10.
LittleB.B.Pharmacokinetics during pregnancy: evidence-based maternal dose formulation.Obstet Gynecol1999; 93: 858–868.
11.
RoustitM., JlaielM., LeclercqP., Stanke-LabesqueF.Pharmacokinetis and therapeutic drug monitoring of antiretrovirals in pregnant women.Br J Clin Pharmacol2008; 66: 179–195.
12.
O'SullivanM.J., BoyerP.J., ScottG.B.The pharmacokinetics and safety of zidovudine in the third trimester of pregnancy for women infected with human immunodeficiency virus and their infants: Phase I acquired immunodeficiency syndrome clinical trials group study (protocol 082).Am J Obstet Gynecol1993; 168: 1510–1516.
13.
MoodleyJ., MoodleyD., PillayK.Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring.J Infect Dis1998; 178: 1327–1333.
14.
WadeN.A., UnadkatJ.D., HuangS.Pharmacokinetics and safety of stavudine in HIV-infected pregnant women and their infants: Pediatric AIDS Clinical Trials Group protocol 332.J Infect Dis2004; 190: 2167–2174.
15.
MirochnickM., SiminskiS., FentonT., LugoM., SullivanJ.L.Nevirapine pharmacokinetics in pregnant women and in their infants after in utero exposure.Pediatr Infect Dis J2001; 20: 803–805.
16.
AcostaE.P., BardeguezA., ZorrillaC.D.Pharmacokinetics of saquinavir plus low-dose ritonavir in human immunodeficiency virus-infected pregnant women.Antimicrob Agents Chemother2004; 48: 430–436.
17.
VillaniP., FloridiaM., PirilloM.F.Pharmacokinetics of nelfinavir in HIV-1-infected pregnant and nonpregnant women.Br J Clin Pharmacol2006; 62: 309–315.
18.
StekA.M., MirochnickM., CapparelliE.Reduced lopinavir exposure during pregnancy.AIDS2006; 20: 1931–1939.
19.
ChappuyH., TréluyerJ.M., ReyE.Maternal-fetal transfer and amniotic fluid accumulation of protease inhibitors in pregnant women who are infected with human immunodeficiency virus.Am J Obstet Gynecol2004; 191: 558–562.
20.
MarzoliniC., RudinC., DecosterdL.A.Transplacental passage of protease inhibitors at delivery.AIDS2002; 16: 889–893.
21.
MirochnickM., DorenbaumA., HollandD.Concentrations of protease inhibitors in cord blood after in utero exposure.Pediatr Infect Dis J2002; 21: 835–838.
22.
CooperE.R., CharuratM., MofensonL.Combination antiretroviral strategies for the treatment of pregnant HIV-1 infected women and prevention of perinatal HIV-1 transmission.J Acquir Immune Defic Syndr2002; 29: 484–494.
